本研究的主要目的是將參與者轉入延伸研究，以收集長期安全性與療效數據。本研究將納入安全耐受bomedemstat、經研究者評估從其使用中獲得臨床獲益，並符合以下條件的參與者： * 來自IMG-7289-202/MK-3543-005（NCT05223920）研究的參與者必須已接受bomedemstat治療至少6個月；
適應症：Thrombocythemia, Essential、Primary Myelofibrosis、Myelofibrosis、Post-polycythemia Vera Myelofibrosis、Post-essential Thrombocythemia Myelofibrosis、Polycythemia Vera
收案條件
納入條件
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \& Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
排除條件
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving \<90% of assigned doses excluding suspensions or holds as assigned by the investigator
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。